Web Exclusives

FDA approves new drug for lupus

The U.S. Food and Drug Administration has approved Benlysta (belimumab) for treatment of lupus. The FDA last approved a drug for lupus in 1955.…

FDA approves new drug for COPD

The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD). Read more…

Fidaxomicin reduces C. diff recurrence

Compared to vancomycin, patients treated with fidaxomicin for Clostridium difficile infection were significantly less likely to have a recurrence. Read more here.

FDA advises women with breast impants

The U.S. Food and Drug Administration says women with breast implants may have a “very small, but increased risk” of developing anaplastic large cell…

FDA approves head lice treatment

The U.S. Food and Drug Administration has approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice in patients 4 years and…

FDA approves new drug for lupus

The U.S. Food and Drug Administration has approved Benlysta (belimumab) for treatment of lupus. The FDA last approved a drug for lupus…

FDA approves new drug for COPD

The U.S. Food and Drug Administration has approved roflumilast, an oral drug that reduces exacerbations from severe chronic obstructive pulmonary disease (COPD).…

Fidaxomicin reduces C. diff recurrence

Compared to vancomycin, patients treated with fidaxomicin for Clostridium difficile infection were significantly less likely to have a recurrence. Read more here.

FDA approves head lice treatment

The U.S. Food and Drug Administration has approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice in patients 4…

Poll

Preferred way to get content

What is your preferred way to consume healthcare content?

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • This field is hidden when viewing the form

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.